Robert Busch, MD

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

An expert panel discusses where bempedoic acid currently fits into the treatment of hypercholesterolemia.

Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.

The role of ezetimibe and PCSK9 inhibitors as treatment for patients who are statin intolerant or require add-on therapy to help reduce cholesterol levels.

What to know about the efficacy of statin therapies used as cholesterol-lowering therapy.

The standard of care for managing high cholesterol levels.

The value of interdisciplinary research and multidisciplinary care of patients at high risk for cardiovascular events.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, presents a case study of a patient with type 2 diabetes mellitus, an insulin pump, and a continuous glucose monitor.

Experts in diabetes discuss the transition to telemedicine during the COVID-19 pandemic and its impact on diabetes care.

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP; Robert Busch, MD; and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide insight into quality-of-life improvements that have followed advances in diabetes technology and review available continuous glucose monitors.

Robert Busch, MD, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss metrics to evaluate diabetes control, including time in range and coefficient of variation.

A panel of experts discuss the impact of continuous glucose monitoring (CGM) on individualized patient care plans for patients with type 1 and type 2 diabetes.

Robert Busch, MD, and Diana Issacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide insight into the use of insulin pumps in type 2 diabetes and describe currently available smart pumps.

Experts in diabetes discuss recent advances in insulin pen technology, including connected and smart pens, and their impact on diabetes care.

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP; Robert Busch, MD; and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide an overview of the pillars of technology utilized in diabetes care: Continuous glucose monitors (CGMs), smart insulin pumps, and connected insulin pens.

A case study for a patient who required additional SGLT-2 inhibitors to help reduce progression of renal disease is presented, and Drs Robert Busch, Dhiren Patel, and Muthiah Vadugananthan share their final thoughts on renal protective agents.

Robert Busch, MD, and Muthiah Vadugananthan, MD, MPH, share their thoughts on the multifunctional responsibility of managing a patient’s renal disease.

Dr Robert Busch and Dr Muthiah Vadugananthan provide insights on educating their peers on the importance of decreasing renal progression.

An expert endocrinologist and cardiologist discuss the risks and complications of renal disease associated with diabetes and cardiovascular disease. Dr Robert Busch also provides an overview of some of the studies done in renal impairment.

Dhiren Patel, PharmD, CECES, BC-ADM, Robert Busch, MD, and Muthiah Vadugananthan, MD, MPH, provide an overview of the prevalence of renal impairment in patients with diabetes.